Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Semaglutide significantly reduced fasting insulin, but not fasting blood glucose
Till now, in bacterial cultures of dairy origin, only S
2024;36(6):1302-1319.e12
NICE guidance on obesity management (CG189) emphasises evidence-based interventions including dietary modification, increased physical activity, behavioural therapy, andwhere appropriatepharmacotherapy with licensed medications such as orlistat or semaglutide (NICE TA875)
High-fat and high-sugar foods, for example, may trigger nausea or other digestive issues